David Lacey, a former senior vice president and head of discovery at Amgen Inc, has joined the supervisory board of the Dutch antibody company, ArGEN-X BV. Dr Lacey, who is retired, was most recently responsible for leading more than 1,200 scientists in Amgen’s discovery research unit across the areas of haematology, oncology, inflammation, metabolic disorders and neuroscience. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the anti-RANKL antibody, denosumab, which was approved in 2010 by the US Food and Drug Administration for osteoporosis.
Dr Lacey holds an MD from the University of Colorado in the US and carried out his postgraduate medical education training and research at Washington University in St Louis, Missouri.
ArGEN-X announced the appointment on 25 October 2012.
Copyright 2012 Evernow Publishing Ltd